Medicament comprising hgf gene

Abstract

The present invention relates to a method for treating insufficiency of peripheral circulation or peripheral angiostenosis in a subject for which HGF is effective, comprising administering to the area affected by the insufficiency of peripheral circulation or peripheral angiostenosis a therapeutically effective amount of an expression vector containing a constitutive promoter operably linked to a HGF coding sequence, whereby the HGF is expressed, promoting the growth of vascular endothelial cells but not vascular smooth muscle cells.

1 . A method for treating insufficiency of peripheral circulation or peripheral angiostenosis in a subject for which HGF is effective, comprising administering to the area affected by said insufficiency of peripheral circulation or peripheral angiostenosis a therapeutically effective amount of an expression vector containing a constitutive promoter operably linked to a HGF coding sequence, whereby said HGF is expressed, promoting the growth of vascular endothelial cells but not vascular smooth muscle cells, thereby treating the insufficiency of peripheral circulation or peripheral angiostenosis. 
   
   
       2 . The method of  claim 1 , wherein said expression vector is a non-viral expression vector containing a HGF coding sequence. 
   
   
       3 . The method of  claim 2 , wherein said non-viral expression vector is encapsulated in a liposome. 
   
   
       4 . The method of  claim 3 , wherein the membrane of said liposome is fused with attenuated Sendai virus particles. 
   
   
       5 . The method of  claim 1 , wherein said expression vector is a viral expression vector containing a HGF coding sequence.